Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group
Phase of Trial: Phase IV
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Ciclosporin (Primary) ; Deferasirox (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 20 Apr 2017 Status changed from recruiting to completed.
- 11 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.